Core Viewpoint - The report indicates a significant decline in revenue and net profit for the first half of 2025, while the international market shows resilience with a 20% increase in revenue compared to the previous year [1][2]. Group 1: Financial Performance - The company's operating revenue for the first half of 2025 was 351 million yuan, representing a year-on-year decrease of 60.07% [1]. - The net profit attributable to shareholders was a loss of 28.31 million yuan, reflecting a year-on-year decline of 117.13% [1]. Group 2: International Market Strategy - The company has implemented a dual-drive strategy focusing on both domestic and international markets, with ongoing efforts in local management and product upgrades [1]. - The international market has shown stability, with revenue growth in countries like India, the Philippines, and Turkey, and several high-speed models have received registration in various countries [1][2]. - The company has shifted from a "multi-point layout" to a "refined cultivation" strategy in the international market, concentrating resources on twelve key countries to enhance competitive strength [2]. Group 3: Product Development and Market Presence - The company has achieved registration for several key products, including biochemical and urine testing instruments, which are now being marketed internationally [1]. - The company’s seven major product series are sold in over 120 countries and regions, establishing stable sales channels and brand influence [2].